CSE Bulletin: Fundamental Change - FogChain Corp./Avisa Diagnostics Inc.

Avisa Diagnostics Inc., the issuer resulting from a Fundamental Change of FogChain Corp. (FOG.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

The Issuer offers an innovative approach to treating lung infections with rapid diagnostics to guide better clinical outcomes.

_________________________________

Avisa Diagnostics Inc., l'émetteur résultant d'un changement fondamental de FogChain Corp.(FOG.X), a été approuvé pour inscription.

Les documents de cotation et de divulgation seront disponibles sur www.thecse.com à la date de négociation.

L'émetteur propose une approche innovante pour traiter les infections pulmonaires avec des diagnostics rapides pour guider de meilleurs résultats cliniques.

Issuer/Émetteur: Avisa Diagnostics Inc.
Security Type/Titre: Common Shares/Actions ordinaires
Symbol(s)/Symbole(s): AVBT
Number of securities issued and outstanding/ Titres émis et en circulation: 41 219 310
Number of Securities reserved for issuance/ Titres réservés pour émission: 25 594 334
CSE Sector/Catégorie: Life Sciences/Sciences biologiques
CUSIP : 05380J 10 7
ISIN : CA 05380J 10 7 5
Old/Vieux CUSIP& ISIN: 34417N105/CA34417N1050
Boardlot/Quotité: 500
Consolidation: 1 New for 15 Old /1 nouveau pour 15 ancien
Trading Currency/Monnaie de négociation: CDN$/$CDN
Trading Date/Date de negociation: le 18 mai/May 2021
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: le 31 décembre/December
Transfer Agent/Agent des transferts: TSX Trust Company

 

The Exchange is accepting Market Maker applications for AVBT. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

The Conversation (0)

FogChain

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance.

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance. Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
US Food and Drug Administration website on a phone screen.

Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status

The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...

Interactive Chart

Latest Press Releases

Related News